Pune: Use Of Plasma Therapy Successful, Claims Sassoon General Hospital Doctor
Pune - The first experimental use of plasma therapy for treating a COVID-19 patient has been successful at Pune's state-run Sassoon general hospital, a senior doctor claimed on Thursday.
A 47-year-old woman, who had co-morbid conditions such as hypertension, hyperthyroid and obesity and who was in critical condition, was given convalescent plasma therapy twice on May 10 and 11.
Read Also: New guidelines for treating most critical COVID-19 patients
"The condition of the patient improved and her repeat tests following the 14-day period came out negative.
The woman has been shifted out of COVID ward and will be given discharge soon," said Dr Murlidhar Tambe, the dean of Sassoon Hospital.
Convalescent Plasma Therapy is an experimental procedure where plasma from the blood of a recovered COVID-19 patient is transfused to a critically ill coronavirus patient.
The blood of a person who has recovered from COVID-19 develops antibodies. When injected into the blood of another patient, these antibodies are supposed to help that person fight the infection.
Read Also: Gujarat designates New hospital building for treatment of COVID 19 patients
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!